Recent advances and mechanisms of action of PD-L1 degraders as potential therapeutic agents
Copyright © 2024 Elsevier Masson SAS. All rights reserved..
PD-L1 is an important immune checkpoint protein that can bind to T cells' PD-1 receptor, thereby promoting immune escape from tumors. In recent years, many researchers have developed strategies to degrade PD-L1 to improve the effect of immunotherapy. The study of degrading PD-L1 provides new opportunities for immunotherapy. Here, we mainly summarize and review the current active molecules and mechanisms that mediate the degradation of immature and mature PD-L1 during the post-translational modification stages, involving PD-L1 phosphorylation, glycosylation, palmitoylation, ubiquitination, and the autophagy-lysosomal process. This review expects that by degrading PD-L1 protein, we will not only gain a better understanding of oncogenic mechanisms involving tumor PD-L1 protein but also provide a new way to improve immunotherapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:268 |
|---|---|
| Enthalten in: |
European journal of medicinal chemistry - 268(2024) vom: 15. März, Seite 116267 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Feng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
B7-H1 Antigen |
|---|
| Anmerkungen: |
Date Completed 18.03.2024 Date Revised 18.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejmech.2024.116267 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369126017 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369126017 | ||
| 003 | DE-627 | ||
| 005 | 20240318234530.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejmech.2024.116267 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1334.xml |
| 035 | |a (DE-627)NLM369126017 | ||
| 035 | |a (NLM)38422701 | ||
| 035 | |a (PII)S0223-5234(24)00147-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Feng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recent advances and mechanisms of action of PD-L1 degraders as potential therapeutic agents |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2024 | ||
| 500 | |a Date Revised 18.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a PD-L1 is an important immune checkpoint protein that can bind to T cells' PD-1 receptor, thereby promoting immune escape from tumors. In recent years, many researchers have developed strategies to degrade PD-L1 to improve the effect of immunotherapy. The study of degrading PD-L1 provides new opportunities for immunotherapy. Here, we mainly summarize and review the current active molecules and mechanisms that mediate the degradation of immature and mature PD-L1 during the post-translational modification stages, involving PD-L1 phosphorylation, glycosylation, palmitoylation, ubiquitination, and the autophagy-lysosomal process. This review expects that by degrading PD-L1 protein, we will not only gain a better understanding of oncogenic mechanisms involving tumor PD-L1 protein but also provide a new way to improve immunotherapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Degradation | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a PD-L1 | |
| 650 | 4 | |a Post-translational modification | |
| 650 | 4 | |a Tumor | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 700 | 1 | |a Jiang, Ruiya |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Shishi |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Caiyun |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Qimeng |e verfasserin |4 aut | |
| 700 | 1 | |a Awadasseid, Annoor |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jianwei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of medicinal chemistry |d 1994 |g 268(2024) vom: 15. März, Seite 116267 |w (DE-627)NLM106608835 |x 1768-3254 |7 nnns |
| 773 | 1 | 8 | |g volume:268 |g year:2024 |g day:15 |g month:03 |g pages:116267 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejmech.2024.116267 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 268 |j 2024 |b 15 |c 03 |h 116267 | ||